Syntara Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Syntara has been growing earnings at an average annual rate of 13.9%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 2.9% per year.
Key information
13.9%
Earnings growth rate
32.8%
EPS growth rate
Pharmaceuticals Industry Growth | 31.2% |
Revenue growth rate | -2.9% |
Return on equity | -292.0% |
Net Margin | -237.1% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified
Jul 05Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Apr 29Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement
Mar 14We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely
Feb 28Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
Oct 27Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque
Mar 01We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth
Jan 04Revenue & Expenses Breakdown
How Syntara makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 6 | -14 | 10 | 0 |
31 Mar 24 | 19 | -10 | 17 | 0 |
31 Dec 23 | 19 | -11 | 16 | 0 |
30 Sep 23 | 12 | -18 | 16 | 0 |
30 Jun 23 | 6 | -13 | 9 | 0 |
31 Mar 23 | 18 | 2 | 15 | 0 |
31 Dec 22 | 8 | -2 | 12 | 0 |
30 Sep 22 | 18 | 2 | 15 | 0 |
30 Jun 22 | 16 | -2 | 15 | 0 |
31 Mar 22 | 14 | -16 | 15 | 0 |
31 Dec 21 | 19 | -12 | 15 | 0 |
30 Sep 21 | 28 | -1 | 16 | 0 |
30 Jun 21 | 24 | -3 | 16 | 0 |
31 Mar 21 | 27 | 5 | 16 | 6 |
31 Dec 20 | 22 | -4 | 16 | -2 |
30 Sep 20 | 12 | -13 | 16 | 6 |
30 Jun 20 | 13 | -14 | 16 | 0 |
31 Mar 20 | 13 | -21 | 17 | 7 |
31 Dec 19 | 13 | -18 | 17 | 7 |
30 Sep 19 | 13 | -18 | 16 | 7 |
30 Jun 19 | 12 | -20 | 17 | 9 |
31 Mar 19 | 7 | -27 | 17 | 9 |
31 Dec 18 | 22 | -12 | 17 | 9 |
30 Sep 18 | 21 | -22 | 17 | 10 |
30 Jun 18 | 49 | 6 | 16 | 10 |
31 Mar 18 | 51 | 10 | 16 | 13 |
31 Dec 17 | 37 | -1 | 16 | 13 |
30 Sep 17 | 36 | 7 | 15 | 13 |
30 Jun 17 | 9 | -18 | 15 | 15 |
31 Mar 17 | 8 | -16 | 15 | 13 |
31 Dec 16 | 7 | -16 | 15 | 14 |
30 Sep 16 | 8 | -14 | 15 | 16 |
30 Jun 16 | 10 | -16 | 15 | 15 |
31 Mar 16 | 47 | 16 | 16 | 17 |
31 Dec 15 | 48 | 14 | 17 | 15 |
30 Sep 15 | 49 | 21 | 19 | 15 |
30 Jun 15 | 47 | 18 | 21 | 13 |
31 Mar 15 | 5 | -34 | 13 | 22 |
31 Dec 14 | 8 | -38 | 25 | 12 |
30 Sep 14 | 5 | -51 | 16 | 17 |
30 Jun 14 | 9 | -52 | 28 | 7 |
31 Mar 14 | 5 | -44 | 18 | 16 |
31 Dec 13 | 6 | -43 | 25 | 13 |
Quality Earnings: SNT is currently unprofitable.
Growing Profit Margin: SNT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SNT is unprofitable, but has reduced losses over the past 5 years at a rate of 13.9% per year.
Accelerating Growth: Unable to compare SNT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: SNT has a negative Return on Equity (-292.01%), as it is currently unprofitable.